(IN BRIEF) The University of Twente, Medisch Spectrum Twente, and the Centre for Human Drug Research (CHDR) will open a new clinical research unit at MST on 10 October 2025. This expansion represents CHDR’s first facility outside Leiden and underscores … Read the full press release
Posted in Education, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Centre for Human Drug Research, Centre for Human Drug Research opens new clinical unit at Medisch Spectrum Twente in partnership with University of Twente, CHDR, clinical research, clinical trials, drug development, Enschede, Healthcare Innovation, Leiden BioScience Park, Leiden University, Leiden University Medical Centre, medical technology, Medisch Spectrum Twente, MST, New clinical research unit at MST marks next step in partnership between University of Twente and Centre for Human Drug Research, TechMed Centre, therapeutic innovation, Twente, University of Twente, University of Twente and partners launch new Centre for Human Drug Research clinical research unit to advance therapeutic innovation in Twente, University of Twente joins CHDR and MST to position Twente as a hub for medical technology and therapeutic development, University of Twente joins forces with CHDR and Medisch Spectrum Twente to open new clinical research unit in Twente, UT
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?